Skip to main content

Table 1 Relationship between MYLK-AS1 and clinicopathological parameters in 156 HCC patients

From: LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma

Clinical variables Number of cases MYLK-AS1 expression P value
Low
N = 78
High
N = 78
Age (years)
  > 50 26 15 11 0.390
  ≤ 50 130 63 67  
Gender
 Male 103 48 55 0.237
 Female 53 30 23  
Tumor number
 Single 125 65 60 0.316
 Multiple 31 13 18  
Etiology
 viral 122 58 64  
 Non-viral 34 20 14 0.245
Serum AFP (ng/ml)
  ≤ 200 75 33 42 0.149
  > 200 81 45 36  
Tumor stage
 I/II 85 52 33 0.002
 III/IV 71 26 45  
Tumor size (cm)
  ≤ 5 62 41 21 0.001
  > 5 94 37 57  
Tumor differentiation
 Well 58 37 21 0.018
 Moderate 49 23 26  
 Poor 49 18 31  
Vascular invasion
 Yes 50 19 31 0.040
 No 106 59 47  
TACE treatment
 Yes 72 28 44 0.010
 No 84 50 34